1.15
29.97%
+0.2652
After Hours:
1.17
0.02
+1.74%
TransCode Therapeutics Inc stock is currently priced at $1.15, with a 24-hour trading volume of 3.90M.
It has seen a +29.97% increased in the last 24 hours and a +129.31% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.8698 pivot point. If it approaches the $1.06 resistance level, significant changes may occur.
Previous Close:
$0.8848
Open:
$0.9097
24h Volume:
3.90M
Market Cap:
$7.02M
Revenue:
-
Net Income/Loss:
$-19.59M
P/E Ratio:
-0.0473
EPS:
-24.29
Net Cash Flow:
$-16.49M
1W Performance:
-18.44%
1M Performance:
+129.31%
6M Performance:
+338.93%
1Y Performance:
-81.14%
TransCode Therapeutics Inc Stock (RNAZ) Company Profile
Name
TransCode Therapeutics Inc
Sector
Industry
Phone
857-837-3099
Address
6 Liberty Square, Suite 2382, Boston
TransCode Therapeutics Inc Stock (RNAZ) Latest News
This trade activity should not be overlooked: TransCode Therapeutics Inc (RNAZ) – Sete News - SETE News
SETE News
TransCode Therapeutics considers reverse stock split By Investing.com - Investing.com Canada
Investing.com Canada
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.21% - MSN
MSN
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.21% - MSN
MSN
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.21% - Investing.com South Africa
Investing.com South Africa
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.21% - Investing.com
Investing.com
TransCode Therapeutics Inc Stock (RNAZ) Financials Data
TransCode Therapeutics Inc (RNAZ) Net Income 2024
RNAZ net income (TTM) was -$19.59 million for the quarter ending September 30, 2023, a -28.64% decrease year-over-year.
TransCode Therapeutics Inc (RNAZ) Cash Flow 2024
RNAZ recorded a free cash flow (TTM) of -$16.49 million for the quarter ending September 30, 2023, a -22.16% decrease year-over-year.
TransCode Therapeutics Inc (RNAZ) Earnings per Share 2024
RNAZ earnings per share (TTM) was -$776.40 for the quarter ending September 30, 2023, a +17.57% growth year-over-year.
TransCode Therapeutics Inc Stock (RNAZ) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Fitzgerald Thomas A | Chief Financial Officer |
Sep 28 '23 |
Buy |
0.51 |
49,350 |
25,168 |
56,318 |
Dudley Robert Michael | Chief Executive Officer |
Jun 21 '23 |
Buy |
2.65 |
12,000 |
31,818 |
82,262 |
Dudley Robert Michael | Chief Executive Officer |
Jun 20 '23 |
Buy |
2.55 |
6,607 |
16,847 |
70,262 |
Dudley Robert Michael | Chief Executive Officer |
Jun 09 '23 |
Buy |
2.76 |
19,000 |
52,440 |
912,114 |
About TransCode Therapeutics Inc
TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, it is developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Cap:
|
Volume (24h):